The KHENERGYZE Study
A Phase IIb Double-blind, Randomised, Placebo-controlled, Multi-centre, Confirmative Three-way Cross-over Study on Cognitive Function With Two Doses of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation.
Sponsor: Julius Clinical
This PHASE2 trial investigates MELAS Syndrome and MIDD and is currently completed. Julius Clinical leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE2
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Julius Clinical
- Khondrion BV
For direct contact, visit the study record on ClinicalTrials.gov .